Pulse Biosciences (NASDAQ:PLSE) Trading 7.6% Higher – Time to Buy?

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares shot up 7.6% during mid-day trading on Friday . The company traded as high as $20.89 and last traded at $21.15. 90,376 shares were traded during mid-day trading, a decline of 26% from the average session volume of 121,426 shares. The stock had previously closed at $19.66.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research note on Thursday, January 2nd.

Pulse Biosciences Stock Up 6.9 %

The business’s fifty day simple moving average is $18.57 and its 200 day simple moving average is $17.76.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same period last year, the company earned ($0.19) earnings per share.

Insider Activity

In other news, CEO Burke Thomas Barrett sold 50,000 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the sale, the chief executive officer now owns 63,172 shares in the company, valued at approximately $1,100,456.24. This represents a 44.18 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert W. Duggan bought 55,256 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were bought at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the completion of the transaction, the director now directly owns 42,328,717 shares of the company’s stock, valued at $727,207,358.06. This trade represents a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 71.50% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

Institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in Pulse Biosciences during the fourth quarter valued at about $193,000. Franklin Resources Inc. purchased a new stake in shares of Pulse Biosciences in the 3rd quarter valued at approximately $378,000. Creative Planning boosted its stake in Pulse Biosciences by 113.9% in the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after purchasing an additional 11,667 shares during the period. Barclays PLC grew its position in Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock worth $530,000 after purchasing an additional 23,738 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pulse Biosciences during the 3rd quarter valued at $588,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.